These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27017976)

  • 1. New drug developments in the management of cystic fibrosis lung disease.
    Turnbull AR; Davies JC
    Expert Opin Pharmacother; 2016 Jun; 17(8):1103-12. PubMed ID: 27017976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for cystic fibrosis.
    Amin R; Ratjen F
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):143-55. PubMed ID: 24479826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies in early clinical development for the treatment of basic defects of cystic fibrosis.
    Dhooghe B; Haaf JB; Noel S; Leal T
    Expert Opin Investig Drugs; 2016; 25(4):423-36. PubMed ID: 26878157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anti-pseudomonal agents for cystic fibrosis- still needed in the era of small molecule CFTR modulators?
    Davies JC; Martin I
    Expert Opin Pharmacother; 2018 Aug; 19(12):1327-1336. PubMed ID: 30101632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.
    Merk D; Schubert-Zsilavecz M
    Expert Opin Drug Discov; 2013 Jun; 8(6):691-708. PubMed ID: 23574506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
    Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
    Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs for cystic fibrosis.
    Wilschanski M; Kerem E
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1285-92. PubMed ID: 21745147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
    Amaral MD
    J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging pharmacotherapies in cystic fibrosis.
    McElvaney OJ; Gunaratnam C; McElvaney OF; Bagwe I; Reeves EP; McElvaney NG
    Expert Rev Respir Med; 2018 Oct; 12(10):843-855. PubMed ID: 30129380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of CFTR modulating therapies for cystic fibrosis.
    Davies JC
    Curr Opin Pulm Med; 2015 Nov; 21(6):579-84. PubMed ID: 26390337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and Emerging Treatments for Cystic Fibrosis.
    Barry PJ; Jones AM
    Drugs; 2015 Jul; 75(11):1165-75. PubMed ID: 26091951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.
    Goralski JL; Davis SD
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S66-73. PubMed ID: 26335956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.